23 completed, 6 recruiting, 5 active not recruiting, 5 terminated. 25 Phase 2, 20 Phase 1, 3 Phase 3, 2 Early Phase 1.
Follow Refractory Hodgkin Lymphoma: new trials by email Literature Review of Refractory Hodgkin Lymphoma trials Research Report on Refractory Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma Pembrolizumab, Non-investigational, involved site radiotherapy (ISRT), Gemcitabine - Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma | Phase 2 | Recruiting | Michael Spinner, MD | 38 | 2026-08-18 | 2026-10-20 |
| An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors HCB301 - Advanced Solid Tumor, Refractory Hodgkin Lymphoma | Phase 1 | Recruiting | FBD Biologics Limited | 50 | 2025-04-02 | 2026-04-13 |
| A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL ATRA, Pembrolizumab - Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 | Recruiting | Rita Assi | 24 | 2024-11-18 | 2026-02-10 |
| Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 32 | 2022-11-03 | 2026-09-10 |
| Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma Brentuximab Vedotin 50 MG [Adcetris] - Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | Hospital Regional de Alta Especialidad del Bajio | 20 | 2022-10-18 | 2025-03-12 |
| PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma PD-1 inhibitor - Hodgkin Lymphoma, Adult, Relapse | Phase 2 | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 47 | 2022-01-01 | 2021-12-17 |
| Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma Basiliximab, Carmustine, Cytarabine - Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 33 | 2021-11-02 | 2025-12-04 |
| Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL Nivolumab, Ipilimumab - Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 13 | 2021-06-04 | 2026-09-16 |
| RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT Evaluation of therapeutical approach after ASCT - Hodgkin Lymphoma, Adult, Relapsed Hodgkin's Disease, Adult | Unknown | Grupo Argentino de Tratamiento de la Leucemia Aguda | 100 | 2021-06-01 | 2024-01-09 | |
| Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma Choline Salicylate, Selinexor - Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Hodgkin Lymphoma | Phase 1 | Completed | Mayo Clinic | 22 | 2021-02-08 | 2026-05-28 |
| Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Acetaminophen, Dexamethasone, Diphenhydramine - Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Completed | City of Hope Medical Center | 13 | 2020-11-18 | 2026-01-28 |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Anti-CD123/CD3 Monoclonal Antibody MGD006 - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Withdrawn | City of Hope Medical Center | 2020-10-20 | 2020-12-17 | |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma Camidanlumab Tesirine - Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 | Completed | ADC Therapeutics S.A. | 117 | 2019-09-13 | 2024-03-28 |
| Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant Busulfan, Gemcitabine, Melphalan - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 50 | 2019-09-13 | 2026-07-30 |
| Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma Nivolumab, Pembrolizumab - Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Early Phase 1 | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 10 | 2019-09-01 | 2026-04-17 |
| Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma Pentamidine - Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 1 | Completed | Reinhold Munker | 1 | 2018-12-19 | 2021-07-07 |
| Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Bendamustine, Gemcitabine, Nivolumab - Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Emory University | 3 | 2018-11-26 | 2025-08-06 |
| Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Belinostat, Carfilzomib, Copanlisib Hydrochloride - Breast Adenocarcinoma, Metastatic Breast Carcinoma | Phase 1 | Terminated | Mayo Clinic | 17 | 2018-03-27 | 2025-05-26 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2017-11-13 | 2026-04-13 |
Showing 20 of 43. Sign in to see all of them.
Hodgkin Disease (43) · Lymphoma, Non-Hodgkin (10) · Leukemia, Lymphocytic, Chronic, B-Cell (9) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (7) · Lymphoma, Mantle-Cell (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Leukemia, Myeloid, Acute (6) · Lymphoma, B-Cell (6) · Lymphoma, Large B-Cell, Diffuse (6) · Lymphoma, T-Cell (6) · Multiple Myeloma (6) · Hematologic Neoplasms (5) · Myelodysplastic Syndromes (5) · Leukemia, Myeloid, Chronic-Phase (4) · Leukemia, Biphenotypic, Acute (3)
Hemic and Lymphatic Diseases (43) · Immune System Diseases (43) · Immunoproliferative Disorders (43) · Lymphatic Diseases (43) · Lymphoproliferative Disorders (43) · Neoplasms by Histologic Type (43) · Lymphoma (41) · Neoplasms (41) · Disease Attributes (14) · Pathologic Processes (14) · Pathological Conditions, Signs and Symptoms (14) · Hematologic Diseases (12) · Lymphoma, Non-Hodgkin (12) · Chronic Disease (11) · Leukemia (11)
Nivolumab (11) · Brentuximab Vedotin (8) · Mycophenolic Acid (8) · Whole-Body Irradiation (7) · fludarabine phosphate (7) · Cyclosporine (6) · Peripheral Blood Stem Cell Transplantation (6) · pembrolizumab (6) · Cyclophosphamide (5) · Cyclosporins (5) · Etoposide (5) · Gemcitabine (5) · CT-P10 (4) · Melphalan (4) · Rituximab (4)
City of Hope Medical Center (8) · Fred Hutchinson Cancer Center (7) · National Cancer Institute (NCI) (4) · M.D. Anderson Cancer Center (3) · Mayo Clinic (3) · University of Washington (2) · ADC Therapeutics S.A. (1) · Barbara Ann Karmanos Cancer Institute (1) · Case Comprehensive Cancer Center (1) · Dana-Farber Cancer Institute (1) · Emory University (1) · FBD Biologics Limited (1) · Grupo Argentino de Tratamiento de la Leucemia Aguda (1) · Hospital Regional de Alta Especialidad del Bajio (1) · Incyte Corporation (1)
United States (38) · Germany (4) · Canada (2) · China (2) · Italy (2) · Argentina (1) · Belgium (1) · Czechia (1) · Denmark (1) · France (1) · Hungary (1) · Mexico (1) · Poland (1) · Puerto Rico (1) · Spain (1)
Ajay Gopal (3) · Alex F Herrera (3) · Brenda Sandmaier (3) · Alex Herrera (2) · Ajay K. Gopal (1) · Bhagirathbhai Dholaria, M.D. (1) · Catherine S Diefenbach (1) · Chitra Hosing (1) · Crystal L Mackall (1) · David Maloney (1) · Dehui Zou, Dr. (1) · Dipenkumar Modi, M.D. (1) · Florencia Negri Aranguren (1) · Grzegorz S. Nowakowski, M.D. (1) · Hayder Saeed, MD (1)
PMID 32499241, PMID 26211987, PMID 29272364, PMID 31248843, PMID 31401903, PMID 31508518, PMID 32192573, PMID 34329577, PMID 35316328, PMID 35622074, PMID 36403579, PMID 39863139, PMID 40811783, PMID 41522540, PMID 41698326
P30CA015704 (8), P30CA033572 (3), P01CA044991 (2), P01CA078902 (2), P30CA016672 (2), 2018 (1), P01CA018029 (1), P01CA229086 (1), P30CA015083 (1), P30CA016087 (1), P30CA022453 (1), P30CA043703 (1), P30CA138292 (1), P50CA097274 (1), P50CA107399 (1)